# The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD

> **NCT01696591** · — · UNKNOWN · sponsor: **Duk Lyul Na** · enrollment: 14 (estimated)

## Conditions studied

- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Delirium, Dementia, Amnestic, Cognitive Disorders
- Mental Disorders

## Interventions

- **BIOLOGICAL:** NEUROSTEM®-AD

## Key facts

- **NCT ID:** NCT01696591
- **Lead sponsor:** Duk Lyul Na
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-03
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2012-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696591, "The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01696591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*